|
1.
|
|
14 p, 623.8 KB |
Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement
/
Caballé Rivera, Alba (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Sánchez, Alba (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Luque, Sonia (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Mur, Isabel (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Puig Sanz, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Crusi, Xavier (Institut d'Investigació Biomèdica Sant Pau. Departament de Cirugia Ortopèdica i Traumatologia) ;
González, José Carlos (Institut d'Investigació Biomèdica Sant Pau. Departament de Cirugia Ortopèdica i Traumatologia) ;
Sorlí, Luisa (Institut Hospital del Mar d'Investigacions Mèdiques) ;
González Osuna, Aránzazu (Institut d'Investigació Biomèdica Sant Pau. Departament de Cirugia Ortopèdica i Traumatologia) ;
Horcajada, Juan Pablo (Universitat Autònoma de Barcelona. Departament de Medicina) ;
Navarro Risueño, Ferran (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia) ;
Benito, Natividad (Universitat Autònoma de Barcelona. Departament de Medicina)
Surgical antimicrobial prophylaxis (SAP) is important for the prevention of prosthetic joint infections (PJIs) and must be effective against the microorganisms most likely to contaminate the surgical site. [...]
2021 -  10.3390/antibiotics10010018
Antibiotics, Vol. 10, Num. 1 (January 2021) , art. 18
|
|
|
2.
|
|
13 p, 3.0 MB |
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis : pooled analyses of two randomized phase clinical trials (re 1 and re 2) through 148 weeks
/
Reich, K. (Dermatologikum Berlin) ;
Warren, R.B. (The University of Manchester. Manchester NIHR Biomedical Research Centre. Salford Royal NHS Foundation Trust) ;
Iversen, L. (Aarhus University Hospital) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Pau-Charles, I. (Almirall R&D) ;
Igarashi, A. (NTT Medical Center Tokyo) ;
Ohtsuki, M. (Jichi Medical University) ;
Falqués, M. (Almirall R&D) ;
Harmut, M. (Almirall R&D) ;
Rozzo, S. (Sun Pharmaceuticals) ;
Lebwohl, M.G. (Icahn School of Medicine at Mount Sinai) ;
Cantrell, W. (University of Alabama at Birmingham) ;
Blauvelt, A. (Oregon Medical Research Center) ;
Thaçi, D. (University of Lübeck) ;
Universitat Autònoma de Barcelona
Tildrakizumab is a specific anti-interleukin-23p19 monoclonal antibody approved for the treatment of plaque psoriasis. To evaluate the long-term efficacy and safety of tildrakizumab treatment for patients with moderate-to-severe psoriasis for up to 148 weeks. [...]
2019 - 10.1111/bjd.18232
British journal of dermatology, Vol. 182 (july 2019) , p. 605-617
|
|
|
3.
|
|
|
4.
|
|
9 p, 453.9 KB |
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis : pooled analysis across six clinical trials
/
Strober, B.E. (Probity Medical Research) ;
Gottlieb, A.B. (New York Medical College at Metropolitan Hospital) ;
van de Kerkhof, P.C.M. (Radboud University Nijmegen Medical Centre) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Bachelez, H. (Sorbonne Paris Cité Université Paris Diderot. Assistance Publique-Hôpitaux de Paris. Service de Dermatologie. Hôpital Saint-Louis) ;
Chouela, E. (Universidad de Buenos Aires) ;
Imafuku, S. (Department of Dermatology. Faculty of Medicine. Fukuoka University) ;
Thaçi, D. (Comprehensive Center for Inflammation Medicine. University Hospital Schleswig-Holstein) ;
Tan, H. (Pfizer Inc.) ;
Valdez, H. (Pfizer Inc.) ;
Gupta, P. (Pfizer Inc.) ;
Kaur, M. (Pfizer Inc.) ;
Frajzyngier, V. (Pfizer Inc.) ;
Wolk, R. (Pfizer Inc.) ;
Universitat Autònoma de Barcelona
Background: Although existing psoriasis treatments are effective and well tolerated in many patients, there is still a need for new effective targeted treatment options. Tofacitinib is an oral Janus kinase inhibitor that has been investigated in patients with moderate-to-severe chronic plaque psoriasis. [...]
2019 - 10.1111/bjd.17149
British journal of dermatology, Vol. 180 Núm. 1 (january 2019) , p. 67-75
|
|
|
5.
|
|
5 p, 332.3 KB |
Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment : Results from the CLEAR study
/
Thaçi, D. (Research Institute and Comprehensive Center for Inflammation Medicine. University of Luebeck) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, K. (Dermatologikum Berlin and SCIderm Research Institute) ;
Tsai, T.F. (Department of Dermatology. National Taiwan University Hospital. National Taiwan University College of Medicine) ;
Tyring, S. (University of Texas Health Science Center and Center for Clinical Studies) ;
Kingo, K. (Dermatology Clinic. Tartu University Hospital. Department of Dermatology. University of Tartu) ;
Ziv, M. (Emek Medical Center) ;
Pinter, A. (Department of Dermatology. University of Frankfurt) ;
Vender, R. (Venderm Innovations in Psoriasis) ;
Lacombe, A. (Novartis Pharma AG) ;
Xia, S. (Novartis Beijing Novartis Pharma Co Ltd) ;
Bhosekar, V. (Novartis Healthcare Pvt Ltd) ;
Gilloteau, I. (Novartis Pharma AG) ;
Guana, A. (Novartis Pharmaceuticals Corporation) ;
Blauvelt, A. (Oregon Medical Research Center) ;
Universitat Autònoma de Barcelona
2019 - 10.1016/j.jaad.2019.04.045
Journal of the American Academy of Dermatology, Vol. 81 Núm. 6 (december 2019) , p. 1405-1409
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
11 p, 1.5 MB |
The role of IL-23 and the IL-23/TH17 immune axis in the pathogenesis and treatment of psoriasis
/
Girolomoni, Giampiero (University of Verona) ;
Strohal, Robert (Federal Academic Teaching Hospital of Feldkirch) ;
Puig Sanz, Lluís (Universitat Autònoma de Barcelona) ;
Bachelez, Herve (Institut Imagine) ;
Barker, Jonathan (King's College London) ;
Boehncke, Wolf-Henning (University of Geneva) ;
Prinz, Joerg (University of Munich)
Psoriasis is a chronic, immune-mediated disease affecting more than 100 million people worldwide and up to 2. 2% of the population. The aetiology of psoriasis is thought to originate from an interplay of genetic, environmental, infectious and lifestyle factors. [...]
2017 - 10.1111/jdv.14433
Journal of the European Academy of Dermatology and Venereology, Vol. 31, Issue 10 (October 2017) , p. 1616-1626
|
|
|
9.
|
|
11 p, 860.0 KB |
Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis : A Model-Based Meta-Analysis
/
Checchio, T. (Pfizer Inc. (USA)) ;
Ahadieh, S. (Pfizer Inc. (USA)) ;
Gupta, P. (Pfizer Inc. (USA)) ;
Mandema, J. (Quantitative Solutions Inc. (USA)) ;
Puig Sanz, Lluís. (Institut d'Investigació Biomèdica Sant Pau) ;
Wolk, R. (Pfizer Inc. (USA)) ;
Valdez, H. (Pfizer Inc. (USA)) ;
Tan, H. (Pfizer Inc. (USA)) ;
Krishnaswami, S. (Pfizer Inc. (USA)) ;
Tallman, A. (Pfizer Inc. (USA)) ;
Kaur, M. (Pfizer Inc. (USA)) ;
Ito, K. (Pfizer Inc. (USA)) ;
Universitat Autònoma de Barcelona
Aggregate data model-based meta-analysis is a regression approach to compare the dose-response and/or time-course across different treatments using summary level data from the literature. Literature search and systematic review following the Cochrane approach yielded 912 sources for investigational and approved treatments for psoriasis. [...]
2017 - 10.1002/cpt.732
Clinical Pharmacology and Therapeutics, Vol. 102, Num. 6 (December 2017) , p. 1006-1016
|
|
|
10.
|
|
13 p, 1.5 MB |
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis : Pooled Analysis of Four Phase 3 Trials
/
Adsit, Sandra (TCR Medical Corporation, San Diego, USA) ;
Zaldivar, Enrique Rivas (Dermos, Guatemala) ;
Sofen, Howard (UCLA School of Medicine, Los Angeles, USA) ;
Dei-Cas, Ignacio (Halitus, Buenos Aires, Argentina) ;
Maldonado-García, César (Centro Dermatológico "Dr. Ladislao de la Pascua", Mexico) ;
Peñaranda, Elkin O. (Riesgo de Fractura S.A., Bogota, Colombia) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Meng, Xiangyi (Novartis Pharmaceuticals Corporation, East Hanover, USA) ;
Fox, Todd (Novartis Pharma AG, Basel, Switzerland) ;
Guana, Adriana (Novartis Pharmaceuticals Corporation, East Hanover, USA) ;
Universitat Autònoma de Barcelona
There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. [...]
2017 - 10.1007/s12325-017-0521-z
Advances in Therapy, Vol. 34 (april 2017) , p. 1327-1339
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
